It's important to choose an option following 2 prior mBC therapies that gives more patients an opportunity for an OS benefit2
References: 1. Planchat E, Abrial C, Thivat E, et al. Late lines of treatment benefit survival in metastatic breast cancer in current practice? Breast. 2011;20(6):574-578. 2. CancerMPact®. Kantar Health. Treatment Architecture: Western Europe Breast Cancer, v1.2. Available from www.cancermpact.com. Published January 2015. Updated May 2015.